Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer

Show full item record



Permalink

http://hdl.handle.net/10138/227971

Citation

Tervahartiala , M , Taimen , P , Mirtti , T , Koskinen , I , Ecke , T , Jalkanen , S & Bostrom , P J 2017 , ' Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer ' , Scientific Reports , vol. 7 , 12682 . https://doi.org/10.1038/s41598-017-12892-5

Title: Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer
Author: Tervahartiala, Minna; Taimen, Pekka; Mirtti, Tuomas; Koskinen, Ilmari; Ecke, Thorsten; Jalkanen, Sirpa; Bostrom, Peter J.
Contributor: University of Helsinki, Department of Pathology
University of Helsinki, Clinicum
Date: 2017-10-04
Language: eng
Number of pages: 9
Belongs to series: Scientific Reports
ISSN: 2045-2322
URI: http://hdl.handle.net/10138/227971
Abstract: Bladder cancer (BC) is the ninth most common cancer worldwide. Radical cystectomy (RC) with neoadjuvant chemotherapy (NAC) is recommended for muscle-invasive BC. The challenge of the neoadjuvant approach relates to challenges in selection of patients to chemotherapy that are likely to respond to the treatment. To date, there are no validated molecular markers or baseline clinical characteristics to identify these patients. Different inflammatory markers, including tumor associated macrophages with their plastic pro-tumorigenic and anti-tumorigenic functions, have extensively been under interests as potential prognostic and predictive biomarkers in different cancer types. In this immunohistochemical study we evaluated the predictive roles of three immunological markers, CD68, MAC387, and CLEVER-1, in response to NAC and outcome of BC. 41% of the patients had a complete response (pT0N0) to NAC. Basic clinicopathological variables did not predict response to NAC. In contrast, MAC387(+) cells and CLEVER-1(+) macrophages associated with poor NAC response, while CLEVER-1(+) vessels associated with more favourable response to NAC. Higher counts of CLEVER-1+ macrophages associated with poorer overall survival and CD68(+) macrophages seem to have an independent prognostic value in BC patients treated with NAC. Our findings point out that CD68, MAC387, and CLEVER-1 may be useful prognostic and predictive markers in BC.
Subject: CYTOTOXIC CHEMOTHERAPY
MACROPHAGE PLASTICITY
ANTICANCER THERAPIES
POLARIZATION
CISPLATIN
MOLECULE
RECEPTOR
SUBSETS
MARKER
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s41598_017_12892_5.pdf 1.326Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record